Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Epigenetic Achilles’ heel of AML

Mutations in genes encoding epigenetic modifiers are frequent in acute myelogenous leukemia (AML) and have been proposed to cause AML via activation of oncogenes and repression of tumor suppressors. Two studies now identify unexpected oncogenic mechanisms and therapeutic vulnerabilities in AML arising from mutations in genes encoding the epigenetic regulators DNMT3A and ASXL1.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Novel oncogenic mechanisms of mutant epigenetic modifiers.


  1. 1.

    The Cancer Genome Atlas Research Network. N. Engl. J. Med. 368, 2059–2074 (2013).

    Article  Google Scholar 

  2. 2.

    Shlush, L. I. et al. Nature 506, 328–333 (2014).

    CAS  Article  Google Scholar 

  3. 3.

    Ueda, K. et al. Cancer Cell 39, 529–547 (2021).

    CAS  Article  Google Scholar 

  4. 4.

    Park, S. J. & Bejar, R. Exp. Hematol. 83, 105–112 (2020).

    CAS  Article  Google Scholar 

  5. 5.

    Scheller, M. et al. Nat. Cancer (2021).

  6. 6.

    Wang, L. et al. Nat. Cancer (2021).

  7. 7.

    Chaudry, S. F. & Chevassut, T. J. BioMed Res. Int. 2017, 5473197 (2017).

    Article  Google Scholar 

  8. 8.

    Russler-Germain, D. A. et al. Cancer Cell 25, 442–454 (2014).

    CAS  Article  Google Scholar 

  9. 9.

    Baylin, S. B. & Jones, P. A. Nat. Rev. Cancer 11, 726–734 (2011).

    CAS  Article  Google Scholar 

  10. 10.

    Treppendahl, M. B., Kristensen, L. S. & Gronbaek, K. J. Clin. Invest. 124, 47–55 (2014).

    CAS  Article  Google Scholar 

  11. 11.

    Muller-Tidow, C. et al. Leukemia 30, 555–561 (2016).

    CAS  Article  Google Scholar 

  12. 12.

    Chiappinelli, K. B. et al. Cell 162, 974–986 (2015).

    CAS  Article  Google Scholar 

  13. 13.

    Roulois, D. et al. Cell 162, 961–973 (2015).

    CAS  Article  Google Scholar 

  14. 14.

    Wolff, F., Leisch, M., Greil, R., Risch, A. & Pleyer, L. Cell Commun. Signal. 15, 13 (2017).

    Article  Google Scholar 

  15. 15.

    Asada, S., Fujino, T., Goyama, S. & Kitamura, T. Cell. Mol. Life Sci. 76, 2511–2523 (2019).

    CAS  Article  Google Scholar 

  16. 16.

    Abdel-Wahab, O. et al. Cancer Cell 22, 180–193 (2012).

    CAS  Article  Google Scholar 

  17. 17.

    Pietras, E. M. Blood 130, 1693–1698 (2017).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Ulrich Steidl.

Ethics declarations

Competing interests

U.S. reports research support and personal fees from Bayer Healthcare; personal fees from Celgene; research support from GlaxoSmithKline; research support and personal fees from Aileron Therapeutics; personal fees and involvement as scientific cofounder and member on the board of directors of Stelexis Therapeutics; personal fees from Pieris Pharmaceuticals; personal fees from Novartis; and personal fees from Vor Biopharma outside the submitted work.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ueda, K., Steidl, U. Epigenetic Achilles’ heel of AML. Nat Cancer 2, 481–483 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing